Dr. Reddy's Laboratories Announces the Launch of Ziprasidone Mesylate for Injection in the U.S. Market

Tuesday, March 17, 2020 Drug News
Email Print This Page Comment bookmark
Font : A-A+

Dr. Reddy’s Laboratories Ltd. (BSE: 500124 NSE: DRREDDY NYSE: RDY along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Ziprasidone Mesylate for Injection 20 mg (base)/mL Single-dose Vials the therapeutic generic equivalent of Geodon® (ziprasidone mesylate) Injection 20 mg/mL approved by the U.S. Food and Drug Administration (USFDA).

“We’re pleased to bring the first generic of Ziprasidone Mesylate for Injection to market for patients who will benefit from access to affordable medicine. With every new product launch we believe we are making healthcare more affordable by delivering value to the pharmacy” explains Marc Kikuchi Chief Executive Officer North America Generics Dr. Reddy’s Laboratories. “This is a great addition to our injectable offering in the U.S. market as we continue to augment our portfolio and drive growth within the hospital segment.”

The Geodon® brand had U.S. sales of approximately $21.8 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health*.

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Ziprasidone mesylate for injection is not approved for the treatment of patients with Dementia-Related Psychosis.


Geodon® is a trademark of Pfizer

*IQIA Retail and Non-Retail MAT January 2020


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store